US9286611077
© PR Newswire
11.12.2025
VNRX
LISTED
XASE
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
News Preview
HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker f...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
VNRX
LISTED
XASE
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
News Preview
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
News Preview
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for pr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
25.11.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
News Preview
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.
Professor Léa Payen, Professor in Toxicology and Biochemistry,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
13.11.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for
Friday, November 14 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-natio...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
VNRX
LISTED
XASE
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
VNRX
LISTED
XASE
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
News Preview
HENDERSON, Nev., Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces participation at the HOPE Animal-Assisted Crisis Response Dogs (HOPE AACR...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
News Preview
HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of i...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
News Preview
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
VNRX
LISTED
XASE
Volition Sponsors Upcoming GenomeWeb Webinar
News Preview
HENDERSON, Nev., Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wed...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
VNRX
LISTED
XASE
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time
HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and...
Themefolio
Profiler
Peergroup
© PR Newswire
28.03.2025
VNRX
LISTED
XASE
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
News Preview
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer
HENDERSON, Nev., March...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.03.2025
VNRX
LISTED
XASE
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
News Preview
HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and D...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
VNRX
LISTED
XASE
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
News Preview
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants
HENDERSON, Nev., March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it ha...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
VNRX
LISTED
XASE
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time
HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth q...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
VNRX
LISTED
XASE
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
News Preview
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity
HENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immuno...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
VNRX
LISTED
XASE
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
News Preview
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1
HENDERSON, Nev., March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Vo...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
VNRX
LISTED
XASE
Volition Proudly Sponsors the 44th ISICEM Congress
News Preview
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21
HENDERSON, Nev., March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISIC...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2025
VNRX
LISTED
XASE
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
News Preview
HENDERSON, Nev., March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, to include Volition's chemiluminescent immun...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
VNRX
LISTED
XASE
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
News Preview
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening.
The study is expected to be completed by the end of 2025
HENDERSON, Nev., March 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrol...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
VNRX
LISTED
XASE
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
News Preview
Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready
HENDERSON, Nev., March 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
28.02.2025
VNRX
LISTED
XASE
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
News Preview
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM
Representatives will also be available at exhibition booth #2943
HENDERSON, Nev., Feb. 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
VNRX
LISTED
XASE
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
News Preview
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies
HENDERSON, Nev., Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method tha...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
VNRX
LISTED
XASE
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
News Preview
HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commerc...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
VNRX
LISTED
XASE
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
News Preview
HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and sept...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
VNRX
LISTED
XASE
Volition Issues Business Review 2024
News Preview
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year.
Volition's major achievements in 2024 include:
Expanded access to the Nu.Q® Vet Cancer Test – now availa...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
VNRX
LISTED
XASE
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
News Preview
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025 at the Beacon Grand Hotel in San Francisco.
HENDERSON, Nev., Dec. 12, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained Li...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
VNRX
LISTED
XASE
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
News Preview
HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
VNRX
LISTED
XASE
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
VNRX
LISTED
XASE
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the thir...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
VNRX
LISTED
XASE
Volition Appoints Timothy I. Still as Chairman
News Preview
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
VNRX
LISTED
XASE
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
News Preview
HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report, from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from s...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
VNRX
LISTED
XASE
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
News Preview
HENDERSON, Nev., Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024, the annual congress of the European Society of Intensive Care Medicine, earlier this week.
Given th...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
VNRX
LISTED
XASE
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
News Preview
HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu....
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
VNRX
LISTED
XASE
Volition Appoints Dr. Ethel Rubin as an Independent Director
News Preview
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Co...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2024
VNRX
LISTED
XASE
Volition Hosts KOL Roundtable on Sepsis
News Preview
HENDERSON, Nev., Sept. 11, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q® NETs technology effe...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2024
VNRX
LISTED
XASE
VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.08.2024
VNRX
LISTED
XASE
VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
News Preview
$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants
HENDERSON, Nev., Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
VNRX
LISTED
XASE
Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
News Preview
HENDERSON, Nev., July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio.
P...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2024
VNRX
LISTED
XASE
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
News Preview
HENDERSON, Nev., June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.
Volition's mid-year review encompasses key highlights including:
Expanding access to the ...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2024
VNRX
LISTED
XASE
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
News Preview
HENDERSON, Nevada, May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City.
Pres...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2024
VNRX
LISTED
XASE
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for
Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024. ...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2024
VNRX
LISTED
XASE
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev., May 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, May 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024,...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2024
VNRX
LISTED
XASE
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
News Preview
HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
Antech's in-clinic version of the...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2024
VNRX
LISTED
XASE
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
News Preview
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year en...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2024
VNRX
LISTED
XASE
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
News Preview
Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev. , March 21, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quar...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2024
VNRX
LISTED
XASE
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
News Preview
HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan....
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2024
VNRX
LISTED
XASE
Volition appoints Dr Andrew Retter as Chief Medical Officer
News Preview
HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
Dr R...
Themefolio
Profiler
Peergroup
© PR Newswire
02.02.2024
VNRX
LISTED
XASE
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
News Preview
HENDERSON, Nev., Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
The webinar takes place on Tuesday, February 13th at 10:30 AM U.S...
Themefolio
Profiler
Peergroup
© PR Newswire
04.01.2024
VNRX
LISTED
XASE
Volition Issues Business Review 2023
News Preview
HENDERSON, Nev., Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
Volition's major achievements in 2023 include:
Launching the Nu.Q® Vet Cancer Test in some significant markets through sev...
Themefolio
Profiler
Peergroup
© Newsfile
03.08.2022
VNRX
LISTED
XASE
VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference
News Preview
Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx Limited's Chief Executive Officer, Cameron Reynolds, will h...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
